Beta-Caryophyllene Exhibits Anti-Proliferative Effects through Apoptosis Induction and Cell Cycle Modulation in Multiple Myeloma Cells.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

Original Publication: Basel, Switzerland : MDPI

Cannabinoid receptors, which are widely distributed in the body, have been considered as possible pharmacological targets for the management of several tumors. Cannabinoid type 2 receptors (CB2Rs) belong to the G protein-coupled receptor family and are mainly expressed in hematopoietic and immune cells, such as B-cells, T-cells, and macrophages; thus, CB2R activation might be useful for treating cancers affecting plasma cells, such as multiple myeloma (MM). Previous studies have shown that CB2R stimulation may have anti-proliferative effects; therefore, the purpose of the present study was to explore the antitumor effect of beta-caryophyllene (BCP), a CB2R agonist, in an in vitro model of MM. Dexamethasone-resistant (MM.1R) and sensitive (MM.1S) human multiple myeloma cell lines were used in this study. Cells were treated with different concentrations of BCP for 24 h, and a group of cells was pre-incubated with AM630, a specific CB2R antagonist. BCP treatment reduced cell proliferation through CB2R stimulation; notably, BCP considerably increased the pro-apoptotic protein Bax and decreased the anti-apoptotic molecule Bcl-2. Furthermore, an increase in caspase 3 protein levels was detected following BCP incubation, thus demonstrating its anti-proliferative effect through apoptosis activation. In addition, BCP regulated AKT, Wnt1, and beta-catenin expression, showing that CB2R stimulation may decrease cancer cell proliferation by modulating Wnt/β-catenin signaling. These effects were counteracted by AM630 co-incubation, thus confirming that BCP's mechanism of action is mainly related to CB2R modulation. A decrease in β-catenin regulated the impaired cell cycle and especially promoted cyclin D1 and CDK 4/6 reduction. Taken together, these data revealed that BCP might have significant and effective anti-cancer and anti-proliferative effects in MM cells by activating apoptosis, modulating different molecular pathways, and downregulating the cell cycle.

Erratum in: Cancers (Basel). 2023 Nov 01;15(21):. (PMID: 37958482)

Int J Mol Sci. 2020 Mar 13;21(6):. (PMID: 32183020)
J Neuroimmune Pharmacol. 2015 Jun;10(2):255-67. (PMID: 25916739)
ACS Omega. 2017 Dec 31;2(12):9080-9094. (PMID: 30023600)
Food Chem Toxicol. 2006 Apr;44(4):538-45. (PMID: 16226832)
Curr Oncol. 2016 Mar;23(2):S23-32. (PMID: 27022311)
Eur J Biochem. 1995 Aug 15;232(1):54-61. (PMID: 7556170)
Front Immunol. 2019 Apr 05;10:721. (PMID: 31024553)
J Cell Physiol. 2019 Mar;234(3):2217-2228. (PMID: 30277583)
Biomed Pharmacother. 2021 Aug;140:111639. (PMID: 34091179)
Int J Mol Sci. 2020 May 27;21(11):. (PMID: 32471216)
Front Pharmacol. 2017 Jan 19;8:2. (PMID: 28154534)
Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9099-104. (PMID: 18574142)
Arch Physiol Biochem. 2019 Oct 4;:1-15. (PMID: 31583906)
Biomolecules. 2019 Jul 31;9(8):. (PMID: 31370242)
Biomedicines. 2020 Jun 17;8(6):. (PMID: 32560286)
Curr Pharm Des. 2018 Dec 8;24(29):3440-3453. (PMID: 30207226)
Int J Cancer. 2017 Feb 1;140(3):674-685. (PMID: 27778331)
Antioxidants (Basel). 2021 Feb 20;10(2):. (PMID: 33672553)
J Cell Physiol. 2019 Feb;234(2):1827-1841. (PMID: 30191949)
Food Chem Toxicol. 2019 Oct;132:110675. (PMID: 31306689)
Clin Cancer Res. 2016 Jan 1;22(1):207-17. (PMID: 26341922)
J Clin Invest. 2012 Oct;122(10):3456-63. (PMID: 23023717)
Br J Pharmacol. 2019 May;176(10):1384-1394. (PMID: 30019449)
Cell Signal. 2005 Jan;17(1):25-37. (PMID: 15451022)
Front Pharmacol. 2018 May 29;9:506. (PMID: 29896101)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
Ann Oncol. 2020 Nov;31(11):1425-1426. (PMID: 32860877)
Nutrients. 2020 Sep 28;12(10):. (PMID: 32998300)
Leukemia. 2019 May;33(5):1063-1075. (PMID: 30770859)
Br J Pharmacol. 2018 Feb;175(4):644-655. (PMID: 29178246)
Fitoterapia. 2020 Jun;143:104553. (PMID: 32184097)
Blood. 2002 Apr 15;99(8):2786-93. (PMID: 11929767)
Mol Carcinog. 2015 Dec;54(12):1796-806. (PMID: 25640641)
Mol Pharmacol. 2006 Sep;70(3):786-92. (PMID: 16772520)
Curr Pharm Des. 2016;22(21):3237-64. (PMID: 26965491)
Leuk Lymphoma. 2018 Nov;59(11):2524-2534. (PMID: 29322846)
Cancers (Basel). 2020 Oct 18;12(10):. (PMID: 33081075)
Int J Mol Sci. 2017 Sep 05;18(9):. (PMID: 28872614)
Cells. 2020 Dec 09;9(12):. (PMID: 33317149)
Cancers (Basel). 2020 Apr 23;12(4):. (PMID: 32340197)
CA Cancer J Clin. 2014 Nov-Dec;64(6):422-44. (PMID: 25266555)
Eur J Med Chem. 2021 Aug 5;220:113539. (PMID: 34034128)
Exp Hematol. 2003 Apr;31(4):271-82. (PMID: 12691914)
Adv Cancer Res. 2020;148:147-169. (PMID: 32723562)

Keywords: Wnt/β-catenin; apoptosis; beta-caryophyllene; cannabinoid receptor 2; multiple myeloma

Date Created: 20211127 Latest Revision: 20231114

20231114

PMC8616110

10.3390/cancers13225741

34830893